It sometimes seems that just as one biotechnology is proven and established, a better version comes along. That's what happened to Ron Berenson when he began looking at technology to form a new company last year.

Berenson, a medical oncologist and the scientific founder of CellPro Inc., has a long-standing interest in antibodies as therapeutics. Last summer, based on the encouraging clinical experience with antibodies in a variety of clinical settings, he began focusing on targeted antibody therapy as a business idea. "But as I did so, I came to appreciate the concerns people have with antibodies: manufacturing, tissue penetration, oral bioavailability, and HAMA responses," he said.